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Abstract
BORIS (CTCFL) is the paralog of CTCF (CCCTC-binding factor; NM_006565), a ubiquitously expressed DNA-binding protein
with diverse roles in gene expression and chromatin organisation. BORIS and CTCF have virtually identical zinc finger
domains, yet display major differences in their respective C- and N-terminal regions. Unlike CTCF, BORIS expression has
been reported only in the testis and certain malignancies, leading to its classification as a ‘‘cancer-testis’’ antigen.
However, the expression pattern of BORIS is both a significant and unresolved question in the field of DNA binding
proteins. Here, we identify BORIS in the cytoplasm and nucleus of a wide range of normal and cancer cells. We compare
the localization of CTCF and BORIS in the nucleus and demonstrate enrichment of BORIS within the nucleolus, inside the
nucleolin core structure and adjacent to fibrillarin in the dense fibrillar component. In contrast, CTCF is not enriched in the
nucleolus. Live imaging of cells transiently transfected with GFP tagged BORIS confirmed the nucleolar accumulation of
BORIS. While BORIS transcript levels are low compared to CTCF, its protein levels are readily detectable. These findings
show that BORIS expression is more widespread than previously believed, and suggest a role for BORIS in nucleolar
function.
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Introduction
CTCFL or BORIS (Brother of the Regulator of Imprinted
Sites), a paralog of CTCF, has been classified as a cancer-testis
antigen as its distribution is reported to be limited to the testis and
certain cancers [1]. Abnormally high levels of BORIS transcripts
are present in a variety of human tumours and cancer-derived cell
lines and, in some, increased expression has been linked to
promoter-specific demethylation and de-repression of co-ex-
pressed cancer-testis genes [2,3,4,5,6,7,8,9,10,11,12]. Different
studies have reported contradictory findings of BORIS expression
in some types of cancer. For example, a reported increased
expression in several breast cancer cell lines and in the majority of
primary breast tumours tested in one study was not confirmed by
another [3,13]. Furthermore, increased transcription levels of
BORIS have been found in melanoma cell lines but not in primary
melanomas [7]. Nevertheless, the importance of BORIS in cancer
is suggested by the finding of high levels in advanced epithelial
ovarian cancer [14].
BORIS and CTCF genes are thought to have evolved during
vertebrate development from a gene duplication event [15]. Whilst
the zinc finger domains that bind DNA in the respective proteins
are very similar, the C- and N-terminal domains of BORIS exhi-
bit no significant homology with CTCF or any other proteins
[16]. BORIS does not contain the modular substrates for specific
post-translational modifications that are critical for CTCF
function and lacks the conserved C-terminal phosphorylation
motif required for CTCF-mediated growth suppression. This
would suggest different functions for the two proteins.
Several lines of evidence point to a role for BORIS in epigenetic
regulation of gene expression. During mouse male germ-line
development, BORIS is observed in primary spermatocytes but is
progressively replaced by CTCF in post-meiotic germ-line cells
[17]. This switch in expression from BORIS to CTCF coincides
with the re-establishment of site-specific DNA-methylation
patterns during male germ cell differentiation [17]. Furthermore,
in tumour cell lines where CTCF silences genes by DNA
methylation, conditional expression of BORIS leads to replace-
ment of CTCF by BORIS at these genes, resulting in local
demethylation and gene activation [6,10,11,18].
The DNA binding and epigenetic functions attributed to
BORIS would suggest a nuclear localization. However, recent
reports show BORIS present mainly in the cytoplasm of prostate
epithelia, testis and prostate cancer cell lines [1] while nuclear
localization is only identified at specific stages of spermatogenesis
and in some 5-aza-dexoxycytidine-treated prostate cancer cell lines
[5]. Here, we show predominant localization of BORIS within the
nucleolus in several cancer cell lines and primary cells, with
enrichment within the nucleolin core structure and adjacent to
fibrillarin in the dense fibrillar component.
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Results and Discussion
BORIS expression in normal and cancer cells and tissues
To determine the level of BORIS expression in normal human
tissues, total RNA was obtained from human adipose, bladder,
brain, cervix, colon, esophagus, kidney, liver, ovary, placenta,
prostate, skeletal muscle, small intestine, spleen, testis, thymus,
thyroid and trachea (Ambion). Real-time RT-PCR showed the
highest BORIS transcript levels in the testis (1010 transcripts/mg
total RNA), while lower levels were detected in the other tissues
(105-108 transcripts/mg total RNA) in agreement with other
reports [7] (Fig. 1). We did not detect BORIS in heart or lung,
although this may be due to a limitation in the sensitivity of our
assay. CTCF transcript levels were relatively constant in all tissues
(109–1010 transcripts/mg total RNA) (Fig 1).
Next, we compared transcript levels of BORIS and CTCF in a
variety of normal and cancer cell lines. Real-time RT-PCR
analysis showed similar levels of BORIS and CTCF mRNA in
fibroblasts, embryonic kidney cells, neural stem cells, neurons,
colorectal, prostate, medulloblastoma, glioblastoma, melanoma
and neuroblastoma cell lines to those observed in human tissues.
BORIS expression was lower (106–107 transcripts/mg total RNA),
compared to the more abundant CTCF (109–1010 transcripts/mg
total RNA) (Fig. 2A). Hence, BORIS and CTCF are present in
both normal and cancer cells, with expression of CTCF often 1000
fold greater.
Unexpectedly, Western blotting showed similar levels of BORIS
expression in normal and tumour cell lines (Fig. 2B). We identified
strong major bands of 60–70 kDa in agreement with the
theoretical molecular weight of BORIS [19]. We also detected
some lower and higher molecular weight bands. It is not yet clear
which of these bands corresponds to the recently described
isoforms of BORIS [19] or which are BORIS with post-
translational modifications. However, incubating the BORIS
antibody with BORIS peptide completely blocked all bands (Fig.
S1). None of these BORIS reactive bands were detected when the
membranes were probed with CTCF antibodies (Fig. 2C).
To confirm the specificity of the BORIS antibody, HEK293T
cells were transfected with GFP-tagged BORIS, or GFP-tagged
CTCF constructs. Western analysis confirmed the presence of
BORIS protein in cells transfected with GFP-tagged BORIS,
whilst only endogenous BORIS was detected in untransfected cells
or cells transfected with GFP-CTCF or empty vector (Fig. S2).
We then used real-time RT–PCR to determine the levels of
BORIS expression in normal mouse tissues including cerebellum,
gut, kidney, liver, ovary, spleen and testis. As in human tissues, we
found a far lower level of BORIS compared to CTCF in mouse
tissues with the exception of the testis (Fig. 3A). Western blotting
on a selection of mouse tissues revealed several bands, the most
abundant of which were at 60–70 kDa (Fig. 3B). We also detected
a band of approximately 48 kDa in the kidney, hippocampus, gut
and the cortex, whilst other less intense bands above 200 kDa were
present in the testis, spleen, lungs and the liver (Fig. 3B). These
higher molecular weight bands may correspond to homo/
heterodimer of BORIS, or poly(ADP)-ribosylation as has been
described for CTCF [20]. Again, no bands were detected when
membranes were probed with BORIS antibodies pre-incubated
with free BORIS peptides (Fig. S3), neither did we detect the same
bands when membranes were probed with CTCF antibodies
(Fig. 3C). Although BORIS protein is clearly detectable, we only
detect low levels of BORIS transcripts, both in cells and tissues
(Fig 1, Fig 2A and Fig 3A). However, discordance between mRNA
level and protein abundance has been reported to be poor for
certain other genes [21,22,23].
In view of the similarity in their zinc finger domains, BORIS
has been suggested to be an antagonist, competitor or regulator of
CTCF in germ cells and human cancers [17]. Indeed, BORIS and
CTCF do compete for binding to common DNA targets. For
example, CTCF occupancy at the MAGE-A1 promoter only
occurs if BORIS expression levels are low [11]. As the N- and C-
terminal ends of BORIS and CTCF are different, they are likely to
be responsible for different functional outcomes, such as mediating
DNA demethylation, after binding to DNA. The relative levels of
BORIS and CTCF are thus likely to be crucial for maintaining
stability in normal gene expression profiles.
Nucleolar localization of BORIS
Immunofluorescence staining showed that BORIS is located
within the cytoplasm and the nucleus of several human cell types,
Figure 1. BORIS and CTCF expression in normal human tissues. BORIS transcript levels in normal human tissues (First choiceH Human Total
RNA Survey Panel, Ambion, UK). Error bars represent the standard deviation.
doi:10.1371/journal.pone.0022399.g001
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including MRC5 fibroblast, HEK293T embyonic kidney cells,
neural stem cells, colorectal, neuroblastoma, melanoma, prostate
and glioblastoma cell lines. In all cell types examined, BORIS
immunoreactivity was enriched in the nucleolus (Fig. 4 and Fig. S4).
Overnight incubation of BORIS antibody with the peptide
completely blocked the immunofluorescent signal further confirm-
ing the specificity of the BORIS antibodies (Fig. S5). No
immunoreactivity was detected when cells were stained with non-
specific IgG antibodies. Co-staining of cells for BORIS or CTCF
and fibrillarin, a highly conserved protein that is associated with
small nucleolar RNAs [24], confirmed enrichment of BORIS but
not CTCF in the nucleolus (Fig. 4A,B). Further co-staining showed
BORIS within the nucleolar space occupied by nucleolin, an
abundant non-ribosomal nucleolar protein [25] (Fig. 4C). Confocal
microscopy and 3D reconstruction confirmed that BORIS was
within the nucleolus, adjacent to fibrillarin in both normal and
cancer cells (Fig. 5A, B and Movies S1, S2, S3 and S4).
To confirm these findings, HEK293T cells were transfected
with GFP-tagged BORIS or GFP-tagged CTCF constructs. Using
live-cell imaging, GFP was found to accumulate progressively in
nucleoli of cells transfected with GFP-BORIS. 71.3% +/2 1.7 of
GFP-BORIS transfected cells showed clear nucleolar localization
(873 cells analysed in total from two independent experiments). In
contrast, cells transfected with GFP-CTCF showed an even
distribution of GFP throughout the nucleus, and those cells
transfected with an empty GFP vector showed mainly GFP in the
cytoplasm (Fig. 6). Furthermore, immunostaining of cells 72 hours
after transfection of HEK293T cells with BORIS specific shRNA
plasmids, but not empty vector, significantly (p,0.05) reduced the
nucleolar immunostaining of BORIS (Fig. S6A, B). This was
accompanied by a corresponding reduction in BORIS transcript
levels (Fig S7).
Putative Nucleolar Localization Sequences
Computational analysis of the BORIS protein sequence
Q8NI51, [26], revealed 2 putative nucleolar localization sequences
in the zinc finger domain:
N LIQHQKTHKNEKRFKCKHCSYACKQ (between posi-
tions 473 and 497) (ZF6/7)
N AKSAASGKGRRTRKRKQTILKEATKGQK (between
positions 573 and 600) (ZF9/10)
Five putative nucleolar localization sequences were predicted in
CTCF, three of which are in the N terminal and overlap with the
CTCF K/R acetylation sites predicted by Klenova, et al. [17].
The predicted nucleolar localization sequences in CTCF are as
follows:
N ESETFIKGKERKTYQRRREGGQEE (between positions
12 and 35)
N KDPDYQPPAKKTKKTKKSKLRYTEEGKDV (between
positions 193 and 221)
N VGNMKPPKPTKIKKKGVKKTFQCEL (between posi-
tions 246 and 270) (N terminal)
N GENGGETKKSKRGRKRKMRSKKEDSSDSENA (be-
tween positions 585 and 615) (ZF 9/10)
N QPVTPAPPPAKKRRGRPPGRTNQPKQNQPTAI (be-
tween positions 639 and 670).
These sequences would support the finding of BORIS in the
nucleolus as well as the translocation of CTCF into the nucleus
during differentiation of human hematopoietic cells [27].
UBF (upstream binding factor) has been recently identified as
the first common interaction partner of BORIS and CTCF [28].
This interaction was shown to be direct and to require the zinc
finger domains of BORIS and CTCF, the high mobility group
(HMG)-box 1, and the dimerization domain of UBF. CTCF was
found to bind immediately upstream of the ribosome spacer
promoter in a methylation-sensitive manner, where it is suggested
to load UBF onto rDNA to form part of a network that maintains
rDNA genes poised for transcription. Our immunofluorescence
staining did not show enrichment of CTCF in the nucleolus,
however, low levels of CTCF may be present but below detection
in our assay. Torrano et al., demonstrated that the translocation of
CTCF to the nucleolus after induction of differentiation in human
and rat cells was regulated by poly(ADP-ribosyl)ation [27]. UBF is
very abundant in the nucleolus and has been shown to be highly
dynamic [29]. Thus, the direct interaction between CTCF and
UBF may be transient and, since BORIS recognizes the same
DNA binding sites [1], there may be competition between CTCF
and BORIS to bind UBF [22]. Taken together with the findings
described here, the direct interaction of BORIS with UBF suggests
BORIS plays an important role in ribosome biogenesis.
Concluding remarks
This is the first report showing BORIS localising predominantly
in the nucleolus in many different malignant and non-malignant cell
types. The nucleolus is a multi-functional sub-nuclear compartment
where for example, ribosomal RNAs are synthesized, processed and
assembled with ribosomal proteins [30,31,32]. However, extensive
proteomic analysis has revealed the dynamic nature of the nucleolar
proteome and suggests that the nucleolus may perform many other
biological roles in addition to ribosome biogenesis such as the
regulation of specific aspects of mitosis and cell cycle progression
[24,33,34]. Here we demonstrate that BORIS is clearly more than a
testis-specific protein, and show a distinct subcellular localization in
multiple cell lines as well as normal human and mouse tissues.
BORIS is enriched in the nucleolus, inside nucleolin core structure
and adjacent to fibrillarin. Our novel finding of widespread
expression of BORIS together with its nucleolar localization
warrants further investigation to ascertain its precise function in
this context.
Materials and Methods
Cell Culture
Cancer cell lines were maintained in RPMI or DMEM
supplemented with 10% fetal bovine serum (unless stated
otherwise), 100-units/ml penicillin, 100-mg/ml streptomycin, and
Figure 2. BORIS and CTCF expression in normal and cancer cell lines. A, BORIS transcript levels in selected cell lines. B, Western blotting for
BORIS showing major bands (*) at approximately 76 KDa (BORIS theoretical size), 60 KDa and 45 KDa. The smaller bands may represent BORIS
isoproteins as described recently [19]. C, Western blotting for CTCF showing major bands (*) at approximately 130 kDa, 60 KDa and 48 KDa. These
different bands may represent differentially expressed CTCF isoforms as described recently [36]. BORIS and CTCF are present in normal cells (neurons,
neural stem cells (NSC) and MRC5 fetal lung fibroblasts), neuroblastoma cell lines (ACN, IMR32 and LAN-1), melanoma cell lines (26258M, A375M and
WM983B), glioblastoma cell lines (CRL-2365, U87MG, CRL-2610, CRL-1620, U138MG and U251) and colorectal cell lines (HCT55, HCT116, HCT15 and
LoVo). D, GAPDH was used as a control for loading differences. Invitrogen NovexHSharp Pre-Stained Protein Standard, LC5800, was used for
determination of band size. Error bars in (A) represent the standard deviation.
doi:10.1371/journal.pone.0022399.g002
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0.29 mg/ml L-glutamine (Invitrogen). Cell lines used were human
lung fibroblasts MRC5 (ECACC); embryonic kidney cell line
HEK293T; colorectal cell lines C99, HCT55, HCT116, HCT15,
LoVo and SW837; medulloblastoma cell line DAOY; prostate
cancer cell lines Du45 and Pnt2; melanoma cell lines A375M, Mel
501, SBCL2, UISO, Mel 6, WM115, WM1158, M2629bM and
WM278; neuroblastoma cell lines ACN, IMR-32 and LAN1 and
glioblastoma cell lines CRL-2365, CRL-2610 (LN-18), CRL-1620
(A-172), CRL-2020, CRL-2611, U-118MG, U-138 MG, U251 and
U87 MG (ATCC). MRC5 cells were grown in the above media,
supplemented with 20% fetal bovine serum. Human neural stem
cells derived from the cell line H9 (46,XX) (EnStem-A, Millipore)
were cultivated in Neurobasal medium (Invitrogen, 21103-049)
supplemented with B27 (Invitrogen, 12587-010), FGF-2 10 ng/ml
(PeproTech), 1% penicillin/streptomycin (Invitrogen) and 2 mM
glutamine (Invitrogen). Half the medium was changed every other
day. In vitro differentiation was induced by omitting FGF-2 from
the medium.
Tissue protein isolation
Mouse tissues were isolated from 3-month-old C57bl6 or NOD
mice and snap frozen in liquid nitrogen. All experimental
protocols involving mouse tissues were approved by the Home
Office Animal Procedures Committee, under the project license
number PPL 70/6693. Tissues were disrupted in Qiagen RLT
lysis buffer for RNA extraction, or into 1X RIPA buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na
Deoxycholate, 0.1% SDS) containing protease inhibitors (Prote-
ase Inhibitor Cocktail Set III EDTA-free, Calbiochem) and
phosphatase inhibitors (Phosphatase Inhibitor Cocktail Set II,
Calbiochem) for protein analysis. Total protein lysates were
prepared from 108 cells in 1X RIPA buffer. Lysed cells were
sonicated briefly with a Bioruptor and debris cleared by
centrifugation. The protein content of the extracts was estimated
using BCA kit (Thermo Fisher Scientific) according to the
manufacturer’s protocol.
RNA Isolation and Reverse Transcription
Total RNA was isolated using silica-based spin-column
extraction kit (RNeasy mini kit, Qiagen) following the manufac-
turer’s protocol. Total RNA was treated with RNase-free DNase1
(Ambion) to reduce genomic DNA contamination. RNA integrity
was evaluated using the Agilent Bioanalyzer. Two micrograms of
total RNA was reverse transcribed with SuperScriptase III
(Invitrogen) using Oligo-dT primers or random hexamers
according to the manufacturer’s protocol. Negative (-RT) controls
contained RNase-free water substituted for reverse transcriptase.
Quantitative Real-Time PCR
Both the published primers [3] and our own designed with
Primer Express 2.0 were used in this study. Together these primers
amplify 19 out of the 23 isoforms of BORIS described recently
[19]. Human primers were as follows:
BORIS exon 4-5 forward:
Figure 3. BORIS and CTCF expression in mouse tissues. A, BORIS
and CTCF mRNA levels in selected normal mouse tissues. B, Western
blotting for BORIS showing major bands (*) at 60–70 KDa and 45 KDa in
mouse tissues. C, Western blotting for CTCF showing bands (*) between
70–100 KDa in mouse tissues. D, GAPDH was used as a control for
loading differences. GE Healthcare Full Range Rainbow Marker,
RPN800E, was used for determination of band size. Error bars in (A)
represent the standard deviation
doi:10.1371/journal.pone.0022399.g003
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59-AAAACCTTCCGTACGGTCACTCT-39
and reverse: 59-TGTTGCAGTCGTTACACTTGTAGG-39
and probe: Fam-TAACACCCACACAGGAACCA-Tam
CTCF exon 5-6 forward: 59-GAGAAGCCATTCAAGTGT-
TCCAT-39
and reverse: 59-CTCCAGTATGAGAGCGAATGTGA-39
and probe: Fam-ATTACGCCAGTGTAGAAGTCAGC-Tam.
Mouse primers were as follows:
BORIS exon 5–6 forward:
59-AGTGCTCCCTGTGCAAGTACG-39
and reverse 59-GTAAGCACACTGGCAACACTGG-39
and probe: Fam-AAGCAAGATGAAGCGTCACAT-Tam
CTCF exon 5–6 forward:
59-TCGTTATAAACACACTCATGAGAAACC-39
and reverse: 59-TCTCCAGTATGAGAGCGAATGTG-39
and probe: Fam-AGTGTTCCATGTGTGATTGTCAG-Tam.
Figure 4. Cellular distribution of BORIS in human cell lines and tissues. A, B Immunofluorescence imaging of BORIS or CTCF staining in
green (Alexa 488) together with fibrillarin staining in red (Alexa 594) in MRC5 and colorectal cell line HCT116 showing enrichment of BORIS, but not
CTCF, within the nucleolus. Cells were counterstained with 49, 6-Diamidino-2-phenylindole (DAPI) shown in blue. BORIS and fibrillarin are close
neighbours with each other and the dense fibrillar component (DFC) of the nucleolus. Images are shown at 100x magnification. C Double
immunostaining showing BORIS staining in green (Alexa 488) within the Nucleolin region (red, Alexa 594) in human neural stem cells and
glioblastoma cell line CRL2365. Cells were counterstained with 49, 6-Diamidino-2-phenylindole (DAPI) shown in blue. Images are shown at 100x
magnification.
doi:10.1371/journal.pone.0022399.g004
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mRNA levels were quantified on an ABI7500 instrument using
SYBR Green JumpStart Taq ReadyMix kit (Sigma-Aldrich) or
platinium Taq polymerase kit (Invitrogen) with 50–100 ng of
cDNA (except for BORIS primers when 150–200 ng of cDNA
was used) and 100–200 nM primers. We used primers spanning
the exon 4/5 junction of BORIS and findings were confirmed
Figure 5. BORIS is adjacent to fibrillarin in the nucleolus. Three-dimensional confocal images showing BORIS staining in green (Alexa 488) and
fibrillarin staining in red (Alexa 594). Cells are counterstained with 49, 6-Diamidino-2-phenylindole (DAPI, blue). A, MRC5 fibroblasts and B, C99
colorectal cell line. Images are shown at 63x magnification.
doi:10.1371/journal.pone.0022399.g005
Figure 6. Transfection of BORIS confirms enrichment in the nucleolus. Live cell imaging of HEK293T cells transiently transfected with GFP-
tagged BORIS (green), GFP-tagged CTCF (green) or empty vector (green), counterstained with Hoechst 333412 (blue). Images are shown at 40x
magnification.
doi:10.1371/journal.pone.0022399.g006
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using published primers to exon 6/7 [2,3], and exon 9/10 [13] in
a qRT-PCR assay with various concentrations of total cellular
RNA. Absolute concentrations were estimated using standard
curves generated from serial dilution of amplicons. The threshold
cycle from serial dilutions of single stranded oligonucleotides was
plotted against the log copy numbers of the target PCR products,
and reported as copy numbers/mg of total RNA [35].
Western Blot Analysis
20–50 mg of protein extract and 10 ul of molecular weight
standard (Invitrogen NovexHSharp Pre-Stained Protein Standard,
LC5800 or GE Healthcare Full Range Rainbow Marker,
RPN800E) were separated on a 4–12% gradient NuPAGE
polyacrylamide gel (Invitrogen) and then blotted onto nitrocelluose
membrane (Invitrogen) according to the manufacturer’s protocol.
The nitrocellulose membrane was incubated in Tris-buffered
saline blocking solution containing 5% skimmed milk and 0.1%
Tween-20. The membrane was then probed with primary
antibodies using standard conditions. We selected two antibodies
against BORIS; a rabbit polyclonal antibody ab18377 (Abcam),
raised against a synthetic peptide within the first 100 amino acids,
and a rabbit polyclonal antibody HPA001472 (Sigma), raised
against amino acids 33–172. These commercially available
antibodies should recognize most of the 23 isoforms of BORIS
and have been characterized previously [13,28]. BORIS antibody
ab18337 (1:1000 dilution, Abcam) was used for all Western data
shown and BORIS antibody HPA001472 (1:200 dilution, Sigma)
was used to confirm the bands (data not shown). For CTCF, we
used antibody 07–729 (1:1000 dilution, Millipore) and for
GAPDH we used antibody 14C10 (1:2000 dilution, Cell
Signalling). After several washes, bands were revealed with the
corresponding horseradish peroxidase coupled secondary antibody
and detected using the ECL detection kit (GE Healthcare)
according to the manufacturer’s protocol.
Immunofluorescence
Cells were grown on coverslips and fixed with 4% paraformal-
dehyde (Electron Microscopy Sciences) in phosphate-buffered
saline, 0.14 M NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.2–7.4 for 10 minutes at room temperature,
followed by permeabilization in blocking buffer (phosphate-
buffered saline containing 0.1% Triton X-100, 0.01% saponin
and 10% goat serum) for 30 minutes at room temperature. Cells
were then incubated with the specific antibodies in blocking buffer
overnight at 4uC. BORIS antibody ab18337 (1:100 dilution,
Abcam) was used for all standard imaging. BORIS antibody
HPA001472 (1:25 dilution, Sigma) was used for confocal imaging
and movies. Staining with both antibodies showed identical
localization. We used CTCF antibody 07–729 (1:1000 dilution,
Millipore), Nucleolin (C23) antibody sc-8031 (1:1000 dilution,
Santa Cruz Biotechnology) and Fibrillarin antibody ab18380
(1:1000 dilution, Abcam). Cells were washed in PBS, and primary
immunoreactions visualized after incubation for 1 hour at room
temperature with the Alexa Fluor 594 chicken anti-mouse IgG, A-
21201 and Alexa Fluor 488 chicken anti-rabbit IgG, A-21441
(both Invitrogen). Nuclei were counterstained with 0.1 mg/ml 49,
6-Diamidino-2-phenylindole (DAPI, Molecular Probes) and cov-
erslips were mounted in Mowiol (Calbiochem). For standard 2
dimensional analysis specimens were visualized using a Zeiss
Axiophot microscope equipped for epifluorescence using Zeiss
plan-neofluar 20x, 40x or 100x objectives. Separate grey-scale
images were recorded with a cooled CCD-camera (Hamamatsu,
Welwyn Garden City, UK). Image analysis was performed using
SmartCapture X software (Digital Scientific, Cambridge, UK).
For 3 dimensional analysis specimens were studied using a Zeiss
Meta 510 LSM using a 63x objective. Deconvolution of images
was performed using Huygens Essential software and images then
processed in Imaris x64 (v7.1.1).
Peptide Competition
Antibody specificity was assessed using a specific blocking
peptide ab22203 (Abcam). 20 ug peptide was added to 10 ug
BORIS antibody ab18337 (Abcam) in 200 ul TBST buffer and
incubated at 37uC overnight. Both blocked and unblocked
antibody was diluted 1:10 in blocking buffer for immunofluores-
cence. All images for both blocked and unblocked antibody were
collected using the same exposure times. BORIS antibody
specificity was also assessed by performing Western blotting with
peptide blocked antibody diluted 1:100 in blocking solution
containing 2 ug/ml blocking peptide. Control unblocked antibody
was incubated at the same time in appropriate blocking buffer
without the addition of blocking peptide.
Cloning and Transfection
Recombinant constructs GFP-BORIS or GFP-CTCF, were
prepared by inserting BORIS or CTCF cDNA into pEGFP-C3
vector (Clontech). Fragments encoding full length BORIS (1–
663aa) and CTCF (1-727) were generated by PCR using the
following primers:
BORIS-GFP forward:
59-CGGAATTCTGATGGCAGCCACTGAGATCTCTGTC-39
and reverse: 59-GCGGGATCCTCACTTATCCATCGTGT-
TGAGGAGC-39
CTCF-GFP forward:
59-CGGAATTCTGATGGAAGGTGATGCAGTCGAAGCC-39
and reverse: 59-GCGGGATCCTCACCGGTCCATCATGC-
TGAGAGGATC-39
and pCMV6-XL5-BORIS or pCMV6-XL5-CTCF plasmids
(Origene) as templates, respectively.
PCR fragments were digested with EcoRI/BamHI inserted into
the pEGFP-C3 MCS in-frame of EGFP. Each construct was
confirmed by sequencing. The resulting GFP-BORIS, GFP-
CTCF and pEGFP-C3 vectors were transfected into HEK293T
cells using FuGene 6-HD (Roche) according to manufacturer’s
protocol. Live transfected cells plated onto glass coverslips were
stained with Hoechst 333412 (Invitrogen) and imaged 48 hours
after transfection. For Western analysis, three million cells were
transfected using FuGene 6-HD (Roche) and cells collected for
protein extraction 72 hours later.
shRNA mediated knockdown of BORIS
HEK293T cells were transiently transfected using purified and
sequence verified plasmids: GI320730 (targeted to a BORIS
specific site encoded by Exon 5 which is included in 19/23 splice
variants identified by Pugacheva et al., [19]), GI320731 (targeted
to a BORIS specific site encoded by Exon 3 which is present in all
23 variants), TR30007 (empty pGFP-V-RS vector) and TR30008
(29-mer Non-Effective GFP (pGFP-V-RS)) from Origene (kit
catalogue number TG305184). Briefly, HEK293T cells were
transfected with shRNA clones GI320730, GI320731, TR30008
or TR30007 using FuGene 6-HD (Roche). Cells were analysed
72 hours after transfection. Three biological replicate shRNA
experiments were performed for each shRNA clone. Quantifica-
tion of mRNA transcripts was performed using RT-PCR and all
data normalized to GAPDH and empty vector set to 1. For
quantification of BORIS immunofluorescence staining, images of
HEK293T cells were collected 72 hours after transfection using
the same exposure time. Images captured from 5 random fields
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containing at least 30 cells were imported into ImageJ software
version 1.44 (Rasband, W.S., ImageJ, U.S. National Institutes of
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/).
Regions of interest (ROI) were created as a mask around DAPI
stained nuclei (blue) and the threshold adjusted to remove
background. Fluorescence intensity was calculated for BORIS
Alexa 594 signal (red) within this mask and mean nuclear
fluorescence was calculated by dividing the total intensity by
nuclear area in each image. Data were exported into Excel and
statistical significance was assessed by One-Way Anova analysis.
Supporting Information
Figure S1 Antibody peptide competition in normal and
cancer cell lines. Western blot analysis using BORIS antibody
ab18337 (Abcam) with and without specific blocking peptide
ab22203 (Abcam). Incubating 20 ug peptide with 10 ug BORIS
antibody ab18337 (Abcam) in 200 ul TBST buffer at 37uC
overnight completely blocked the bands obtained using un-blocked
antibody. Both blocked and un-blocked BORIS antibody was used
at a dilution of 1:100 in blocking buffer containing 2 ug/ml of
peptide.
(TIF)
Figure S2 Western confirmation of BORIS antibody
specificity. HEK293 cells transiently transfected with GFP-
BORIS, GFP-CTCF or pEGFP-C3 empty vector (Clontech).
Membranes probed with GFP, BORIS, CTCF or GAPDH
antibodies. GFP-BORIS migrates at approximately 100 KDa,
GFP-CTCF migrates at 140 KDa and GFP alone at 30 KDa. In
comparison to the strong bands detected for GFP-BORIS,
endogenous BORIS migrates at 50–70 KDa as much weaker
bands. GAPDH was used as a control for loading differences.
Invitrogen NovexHSharp Pre-Stained Protein Standard, LC5800,
was used for determination of band size.
(TIF)
Figure S3 Antibody peptide competition in mouse
tissues. Western blot analysis using BORIS antibody ab18337
(Abcam) with and without specific blocking peptide ab22203
(Abcam). Incubating 20 ug peptide with 10 ug BORIS antibody
ab18337 (Abcam) in 200 ul TBST buffer at 37uC overnight
completely blocked the bands obtained using un-blocked antibody.
Both blocked and un-blocked BORIS antibody was used at a
dilution of 1:100 in blocking buffer containing 2 ug/ml of peptide.
(TIF)
Figure S4 Distribution of BORIS in various cell lines.
Immunofluorescence imaging of BORIS in green (Alexa 488)
together with fibrillarin in red (Alexa 594), counterstained with 49,
6-Diamidino-2-phenylindole (DAPI) in blue showing enrichment
of BORIS within the nucleoli of A, neuroblastoma cell lines, B,
colorectal cell lines, C, prostate cancer cell line and D, melanoma
cell lines. Images are shown at 100x magnification.
(TIF)
Figure S5 Antibody peptide competition in MRC5 cells.
Immunofluorescence imaging of BORIS in red (Alexa 594) without
peptide competition (A) and peptide neutralised BORIS antibody
(B) counterstained with 49, 6-Diamidino-2-phenylindole (DAPI) in
blue. Images were obtained using identical exposure times and
processing for a direct comparison of antibody versus antibody-
peptide competition. Both blocked and un-blocked BORIS
antibody was used at a dilution of 1:10 in blocking buffer containing
2 ug/ml of peptide. Images are shown at 100x magnification.
(TIF)
Figure S6 Immunofluorescence staining of HEK293T
cells after BORIS knockdown. A, HEK293T cells transiently
transfected with BORIS-specific shRNA, GI320730 (Exon 5 in
NM_080618.2) or GI320731 (Exon 3, NM_080618.2), empty
vector (TR30007) or scrambled control (TR30008). shRNA
vectors express GFP (green) as a transfection reporter and cells
were stained for BORIS (red) 72 hours after transfection. Cells
were counterstained with 49, 6-Diamidino-2-phenylindole (DAPI)
shown in blue. Note the almost complete absence of nucleolar
BORIS in GI320730 and GI320731 transfected cells (green).
Images are shown at 40x magnification. B, Quantification of
nuclear BORIS in A. Data is expressed as mean nuclear intensity
(arbitrary units, AU) of all cells in 5 random fields with at least 30
cells per field and represents the data from 3 biological repeats. p-
values in B were calculated by one-way ANOVA as compared to
nuclear intensity in cells transfected with scrambled control. Error
bars represent the standard deviation.
(TIF)
Figure S7 Transient knockdown of BORIS in HEK293T
cells. Quantification of BORIS and CTCF transcripts in
HEK293T cells after transient transfection with with BORIS-
specific shRNA, GI320730 (Exon 5 in NM_080618.2) or
GI320731 (Exon 3, NM_080618.2) or empty vector (TR30007).
Data is normalised to GAPDH and empty vector set to 1. Error
bars represent the standard deviation.
(TIF)
Movie S1 MRC5 fibroblast nucleus stained with BORIS
in green (Alexa 488) and fibrillarin in red (Alexa 594),
with 49, 6-Diamidino-2-phenylindole (DAPI) counter-
staining in blue. BORIS immunoreactivity is enriched in the
nucleolus adjacent to fibrillarin. Optical sections were obtained by
confocal microscopy using a Zeiss Meta 510 LSM, and three-
dimensional reconstruction performed using Imaris x64 (v7.1.1).
Images are shown at 63x magnification.
(AVI)
Movie S2 MRC5 fibroblast nucleus stained with BORIS
in green (Alexa 488) and fibrillarin in red (Alexa 594),
with 49, 6-Diamidino-2-phenylindole (DAPI) counter-
staining in blue. BORIS immunoreactivity is enriched in the
nucleolus adjacent to fibrillarin. Optical sections were obtained by
confocal microscopy using a Zeiss Meta 510 LSM, and three-
dimensional reconstruction performed using Imaris x64 (v7.1.1).
Surface reconstruction of each channel was performed with colour
properties and transparency adjusted to show spatial distribution
of BORIS with respect to fibrillarin in the nucleolus. Images are
shown at 63x magnification.
(AVI)
Movie S3 Nucleus from a colorectal cell line, C99,
stained with BORIS in green (Alexa 488) and fibrillarin
in red (Alexa 594), with 49, 6-Diamidino-2-phenylindole
(DAPI) counterstaining in blue. BORIS immunoreactivity is
enriched in the nucleolus adjacent to fibrillarin. Optical sections
were obtained by confocal microscopy using a Zeiss Meta 510
LSM and three-dimensional reconstruction performed using
Imaris x64 (v7.1.1). Images are shown at 63x magnification.
(AVI)
Movie S4 Nucleus from a colorectal cell line, C99,
stained with BORIS in green (Alexa 488) and fibrillarin
in red (Alexa 594), with 49, 6-Diamidino-2-phenylindole
(DAPI) counterstaining in blue. BORIS immunoreactivity is
enriched in the nucleolus adjacent to fibrillarin. Optical sections
were obtained by confocal microscopy using a Zeiss Meta 510
BORIS/CTCFL Widespread Expression
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LSM and three-dimensional reconstruction performed using
Imaris x64 (v7.1.1). Surface reconstruction of each channel was
performed with colour properties and transparency adjusted to
show spatial distribution of BORIS with respect to fibrillarin in the
nucleolus. Images are shown at 63x magnification.
(AVI)
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